REFERENCES

Wyndham CR. Atrial fibrillation: the most common arrhythmia. Tex Heart Inst J .
2000;27:257-267.
  1. Bukari A, Nayak H, Aziz Z, Deshmukh A, Tung R and Ozcan C. Impact of race and gender on clinical outcomes of catheter ablation in patients with atrial fibrillation. Pacing Clin Electrophysiol . 2017;40:1073-1079.
  2. Wolbrette D. Antiarrhythmic Drugs: Age, Race, and Gender Effects.Card Electrophysiol Clin . 2010;2:369-378.
  3. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH, Jr., Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M and Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.Circulation . 2014;129:837-847.
  4. Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB and Copenhagen City Heart S. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). The American journal of cardiology . 2004;94:889-894.
  5. Lip GY, Laroche C, Boriani G, Cimaglia P, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Popescu MI, Tica O, Hellum CF, Mortensen B, Tavazzi L and Maggioni AP. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace . 2015;17:24-31.
  6. Asad Z, Abbas M, Javed I, Korantzopoulos P and Stavrakis S. Obesity is associated with incident atrial fibrillation independent of gender: A meta-analysis. J Cardiovasc Electrophysiol . 2018;29:725-732.
  7. Piccini JP, Hammill BG, Sinner MF, Jensen PN, Hernandez AF, Heckbert SR, Benjamin EJ and Curtis LH. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes . 2012;5:85-93.
  8. Piccini JP, Hammill BG, Sinner MF, Hernandez AF, Walkey AJ, Benjamin EJ, Curtis LH and Heckbert SR. Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. European heart journal . 2014;35:250-256.
  9. Dewland TA, Olgin JE, Vittinghoff E and Marcus GM. Incident atrial fibrillation among Asians, Hispanics, blacks, and whites.Circulation . 2013;128:2470-2477.
  10. Shen AY, Contreras R, Sobnosky S, Shah AI, Ichiuji AM, Jorgensen MB, Brar SS and Chen W. Racial/ethnic differences in the prevalence of atrial fibrillation among older adults–a cross-sectional study.J Natl Med Assoc . 2010;102:906-913.
  11. Magnani JW, Norby FL, Agarwal SK, Soliman EZ, Chen LY, Loehr LR and Alonso A. Racial Differences in Atrial Fibrillation-Related Cardiovascular Disease and Mortality: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA cardiology . 2016;1:433-441.
  12. Tahhan AS, Vaduganathan M, Greene SJ, Fonarow GC, Fiuzat M, Jessup M, Lindenfeld J, O’Connor CM and Butler J. Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. JAMA cardiology. 2018;3:1011-1019.
  13. Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A, Pieper KS, Dolor RJ, Douglas PS, Mark DB and Newby LK. Representation of women in randomized clinical trials of cardiovascular disease prevention.Circ Cardiovasc Qual Outcomes . 2010;3:135-142.
  14. Scott PE, Unger EF, Jenkins MR, Southworth MR, McDowell TY, Geller RJ, Elahi M, Temple RJ and Woodcock J. Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs. Journal of the American College of Cardiology . 2018;71:1960-1969.
  15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J and Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ . 2009;339:b2700.
  16. Khan SU, Khan MU, Ghani AR, Lone AN, Arshad A and Kaluski E. Meta-Analysis of Antithrombotic Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention. The American journal of cardiology . 2018;121:1200-1206.
  17. Khan SU, Rahman H, Talluri S and Kaluski E. The Clinical Benefits and Mortality Reduction Associated With Catheter Ablation in Subjects With Atrial Fibrillation: A Systematic Review and Meta-Analysis. JACC Clinical electrophysiology . 2018;4:626- 635.
  18. FDA. Collection of Race and Ethnicity Data in Clinical Trials. 2016.
  19. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY and Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.European heart journal . 2006;27:949-953.
  20. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV and Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.Jama . 2001;285:2370-2375.
  21. Kodani E and Atarashi H. Prevalence of atrial fibrillation in Asia and the world.
Journal of Arrhythmia. 2012;28:330-337.
  1. Nisar MU, Munir MB, Sharbaugh MS, Thoma FW, Althouse AD and Saba S. Trends in atrial fibrillation hospitalizations in the United States: A report using data from the National Hospital Discharge Survey.Indian Pacing Electrophysiol J . 2018;18:6-12.
  2. Zarifis J, Beevers G and Lip GY. Acute admissions with atrial fibrillation in a British multiracial hospital population. The British journal of clinical practice . 1997;51:91- 96.
  3. Davis RC, Hobbs FD, Kenkre JE, Roalfe AK, Iles R, Lip GY and Davies MK. Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. Europace . 2012;14:1553-1559.
  4. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D’Agostino RB, Massaro JM, Beiser A, Wolf PA and Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation . 2004;110:1042-1046.
  5. Guo Y, Tian Y, Wang H, Si Q, Wang Y and Lip GYH. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest . 2015;147:109-119.
  6. Shulman E, Kargoli F, Mittell A, Hoch E, DiBiase L, Fisher J, Gross J, Kim S, Ferrick KJ and Krumerman A. 073_16751-H1 Atrial Fibrillation in Hispanics, Blacks and Whites with Heart Failure. JACC: Clinical Electrophysiology . 2017;3:S5.
  7. Health E. Do Clinical Trials Have a Sex Problem? 2018.
  8. Merkatz RB. Inclusion of women in clinical trials: a historical overview of scientific, ethical, and legal issues. J Obstet Gynecol Neonatal Nurs . 1998;27:78-84.
  9. Krecic-Shepard ME, Park K, Barnas C, Slimko J, Kerwin DR and Schwartz JB. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther . 2000;68:130-142.
  10. Skolnick AH and Alexander KP. Older Adults in Clinical Research and Drug Development: Closing the Geriatric Gap. Circ Cardiovasc Qual Outcomes . 2015;8:631- 633.
  11. Informed Consent of Subjects Who Do Not Speak English (1995).
  12. Hussain-Gambles M, Atkin K and Leese B. Why ethnic minority groups are under-represented in clinical trials: a review of the literature.Health Soc Care Community . 2004;12:382-388.
  13. McCullough LB, Coverdale JH and Chervenak FA. Preventive ethics for including women of childbearing potential in clinical trials. Am J Obstet Gynecol . 2006;194:1221- 1227.
Table 1Table 1. Trends in Age, Sex, and Race/Ethnicity of Contemporary Clinical Trials of Atrial Fibrillation (1989-2019)